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provided it is propeObjective: This study compared 12-month CD4þ and viral load outcomes in HIV-
infected children and adolescents with virological failure, managed with four treatment
switch strategies.
Design: This observational study included perinatally HIV-infected (PHIV) children in
the Pediatric HIV/AIDS Cohort Study (PHACS) and Pediatric AIDS Clinical Trials
(PACTG) Protocol 219C.
Methods: Treatment strategies among children with virologic failure were compared:
continue failing combination antiretroviral therapy (cART); switch to new cART; switch
to drug-sparing regimen; and discontinue all ART. Mean changes in CD4þ% and viral
load from baseline (time of virologic failure) to 12months follow-up in each group were
evaluated using weighted linear regression models.
Results: Virologic failure occurred in 939 out of 2373 (40%) children. At 12 months,
children switching to new cART (16%) had a nonsignificant increase in CD4þ% from
baseline, 0.59 percentage points [95% confidence interval (95% CI)1.01 to 2.19], not
different than those who continued failing cART (71%) (0.64 percentage points,
P¼0.15) or switched to a drug-sparing regimen (5%) (1.40 percentage points, P¼0.64).
Children discontinuing all ART (7%) experienced significant CD4þ% decline 3.18
percentage points (95% CI 5.25 to 1.11) compared with those initiating new cART
(P¼0.04). All treatment strategies except discontinuing ART yielded significant mean
decreases in log10VL by 12 months, the new cART group having the largest drop (1.15
log10VL).
Conclusion: In PHIV children with virologic failure, switching to new cART was
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2110 AIDS 2015, Vol 29 No 16worst immunologic and virologic outcomes and should be avoided. Drug-sparing
regimens and continuing failing regimens may be considered with careful monitoring.
Copyright  2015 Wolters Kluwer Health, Inc. All rights reserved.AIDS 2015, 29:2109–2119Keywords: CD4þ and viral load outcomes, HIV-infected children, virological
failureIntroduction
The benefits of early combination antiretroviral therapy
(cART) in HIV-infected children are well described and
include improvement in virologic and immunologic
parameters and reductions in mortality, hospital admis-
sions and comorbidities such as HIVencephalopathy and
cardiomyopathy [1–6]. The WHO recommends
initiation of cART in all HIV-infected children under
5 years of age [1,7]. However, sustaining the benefits of
early treatment requires lifelong adherence to cART,
which is hampered by dependence on caregivers for
cART administration, poor palatability of drugs, pill
burden and frequency of administration, drug toxicities
and developmental changes, especially during adoles-
cence [8–10].
Globally, excellent virologic suppression rates in children
receiving cART have been described with over 80% viral
suppression at 36-month follow-up [11,12]. However,
30–40% of children develop virologic failure over time
[13]. In children who develop virologic failure, switching
to a new cART regimen on the basis of viral drug
resistance testing can lead to virologic suppression.
Success of this approach relies on overcoming adherence
barriers and on the availability of potent drugs to
construct a new cARTregimen to which the child’s virus
is susceptible. In resourced settings, highly treatment-
experienced children with prior exposure to numerous
antiretroviral drugs are presented with the challenges of
multiresistant HIV and lack of active drugs [14]. In
resource-limited settings, in which financial and struc-
tural constraints limit access to new drugs, it is often
difficult to access potent new cARTregimens for children
with virologic failure on first-line therapy.
As more children access cART globally, challenges
around optimal management of virologic failure are
likely to intensify. Treatment options explored by various
studies include optimizing therapy with a new CART
regimen [15]; continuing with a failing regimen [16];
switching to a simplified, non-cART drug-sparing
regimen [17]; and treatment interruption [18]. No
studies to date have directly compared immunological
and virologic outcomes with these treatment options in
children with virologic failure.We used observational data from two large US-based
prospective cohorts of perinatally infected children and
adolescents (PHIV) to address this question. Among
PHIV with virologic failure after at least 6 months of
cART, we compared immunological and virologic
outcomes 12 months after virologic failure in children
managed with the following treatment options: continue
with current failing cART; switch to a new cART; switch
to a non-cART, drug-sparing regimen and discontinue
all ART.Materials and methods
Study population
The source populations were the Adolescent Master
Protocol (AMP) of the Pediatric HIV/AIDS Cohort
Study (PHACS) and the Pediatric AIDS Clinical Trials
(PACTG) Protocol 219C. These prospective cohort
studies were designed to evaluate the impact of HIV
infection and cARTon children with perinatal infection
and enrolled over 2700 PHIV children and adolescents
from 1993 to 2009. The protocols were approved by
Institutional Review Boards at each participating site;
written informed consent was obtained from each
participant or participant’s parent or legal guardian, as
appropriate. For the final study population, we selected
PHIV children with documented virologic failure after at
least 6 months of cARTwho had covariate information
available at the time of virologic failure. The most recent
virologic failure event was included in the analysis.
Study definitions
cARTwas defined as a regimen consisting of at least three
antiretroviral drugs from at least two different drug classes.
Virologic failure was defined as an HIV plasma viral load
more than 1000 copies/ml on at least two consecutive
occasions at least 1 month apart, with no intervening
values of 1000 copies/ml or less, after receiving at least 6
months of cART. The date of confirmed virologic failure
was defined as the date of the second elevated virologic
failure and used as baseline.
The treatment strategies after documented virologic
failure on cARTwere defined as follows:
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failing cART regimen or addition, subtraction or
substitution of a single antiretroviral drug, with no change
in drug classes, still meeting the definition of cART
(2) Switch to new cART: the addition, subtraction or
substitution of least two antiretroviral drugs and/or
addition of at least one antiretroviral drug from a new
drug class, while still meeting the definition of cART
(3) Switch to a drug-sparing regimen: a regimen not
meeting the above definition of cART (one or more
drugs from a single class or one drug from each of two
classes)
(4) Discontinuation of all antiretroviral drugs
All decisions regarding changes in treatment regimen
were made by the patient, the family and clinician. PHIV
children in our study population were followed from
baseline to 12 months after virologic failure, death or loss
to follow-up, whichever came first. The outcomes of
interest were change in CD4þ% and viral load from
baseline to 12 months after virologic failure. Covariates
considered as potential confounders of the association
between treatment switch strategies and the immunologic
and virologic outcomes included age at baseline, sex,
calendar year of cART failure, having a previous cART
failure, nadir CD4þ%, CD4þ% (baseline and time-
varying), viral load (baseline and time-varying), Centers
for Disease Control and Prevention (CDC) classification
at baseline, antiretroviral drug adherence (self/caregiver-
reported at baseline and time-varying), height (HAZ) and
weight (WAZ) for age z-scores (baseline and time-
varying), and increases in toxicity grade of the following
laboratory measures (time-varying): creatinine, alanine
aminotransferase, lipase, absolute neutrophil count,
haemoglobin, platelets and white blood cell count.
Statistical analysis
For each outcome, we estimated the mean change from
baseline to 12 months for each of the four treatment
strategies initiated within 6 months of cART failure. A
weighted linear regression model for change from
baseline was fit for each outcome, including treatment
strategy, sex, cART failure year, previous cART failure
and baseline measures of age, nadir CD4þ%, CDC class,
antiretroviral drug adherence, HAZ, and WAZ. Baseline
CD4þ% was only included in the change in viral load
outcome model and baseline viral load was only included
in the change in CD4þ% outcome model. Toxicity was
graded according to Division of AIDS (DAIDS) toxicity
tables [19]. Robust standard errors were calculated to
compute 95% confidence intervals around the parameter
estimates.
To adjust for prognostic factors that may have influenced
clinical decision to choose one of the four treatmentstrategies after virologic failure, we implemented a
statistical modelling approach that has been previously
described to evaluate when to start strategies in HIV-
infected adults [20]. Briefly, this strategy creates exact
copies of each child and assigns one copy to each of the
four treatment strategies. Each child copy is censored if
and when the child’s data were no longer consistent with
the strategy assigned to the copy. To adjust for the
potential bias resulting from this censoring, inverse
probability weights were estimated using multinomial
logistic models for the time-varying probability of each
treatment strategy in the original study population. The
models included the covariates previously listed along
with time-varying antiretroviral drug adherence, HAZ,
WAZ, CD4þ%, viral load and interval of follow-up time.
Inverse probability weights for censoring due to loss-to-
follow-up were also estimated using logistic regression
models including treatment and the previously listed
baseline and time-varying covariates. Consistent with
previous studies, inverse probability weights were
truncated at a maximum value of 10 [20]. The estimated
weights were then applied to the outcome models
described previously. Under our assumptions, the
parameters of the weighted model validly estimate the
parameters of a marginal structural model. All analyses
were conducted using SAS version 9.2 (SAS Institute,
Cary, North Carolina, USA).Results
There were 2747 PHIV children in the AMP and 219C
cohorts. Of these, 2433 (89%) were ever on cARTwith
2373 (98%) receiving cART for at least 6 months.
Virologic failure was observed in 939 (40%) of the
children receiving cART for at least 6 months after a
median of 23 months [interquartile range (IQR) 14–38].
Among these 939 children, 15% experienced one and 1%
experienced two or more prior episodes of virologic
failure (Table 1). The majority (90%) of virologic failure
occurred prior to 2007. Of the failing cART regimens,
85% (n¼ 800) contained a protease inhibitor, of which
20% (n¼ 164) also contained a nonnucleoside reverse
transcriptase inhibitor (NNRTI). Nelfinavir was included
in 45% and lopinavir/ritonavir in 33% of failing protease
inhibitor based cART regimens. Of failing cART
regimens, 32% included NNRTIs, either efavirenz
(52%) or nevirapine (47%). (Table 1)
Observed treatment strategies for children with
virologic failure
Of the 939 children who failed cART, 735 (78%) had
complete baseline covariate information for analyses
comparing immunologic and virologic outcomes by
treatment strategy after virologic failure. Half of this
analytic population was female and 63% were black, non-
Hispanic (Table 2) [21,22]. At the time of virologic failure
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Table 1. Characteristics of most recent combination antiretroviral therapy failure among individuals with virologic failure after at least 6 months
of combination antiretroviral therapy (NU939)a.
Characteristics N (%)/median (Q1, Q3)
Previous cART failuresc None 790 (84%)
One 138 (15%)
Two or more 11 (1%)
cART initiation and failure year Year Initiation Failure
1993–1997 82 (9%) 3 (0%)
1998–2000 365 (39%) 67 (7%)
2001–2011 492 (52%) 869 (93%)
Type of failed cART: NRTI(s) þ One PIc 627 (67%)
PI and NNRTI 159 (17%)
NNRTI alone 137 (15%)
PI and EI/INSTI 9 (1%)
PI, NNRTI and EI/INSTI 5 (1%)
NNRTI and EI/INSTI 2 (0%)
PI in failed cART Nelfinavir 360 (38%)
Lopinavir/ritonavir 260 (28%)
Amprenavir 64 (7%)
Atazanavir 59 (6%)
Saquinavir 46 (5%)
Indinavir 29 (3%)
Fosamprenavir 19 (2%)
Tipranavir 5 (1%)
Boosted Darunavir 4 (0%)
NNRTI in failed cART Efavirenz 159 (17%)
Nevirapine 143 (15%)
Etravirine 2 (0%)
EI/INSTI in failed cART Enfuvirtide 11 (1%)
Raltegravir 5 (1%)
Maraviroc 1 (0%)
Log10 viral load at cART initiation
b Median (Q1, Q3) 4.2 (3.5, 4.8)
Missing 417 (44%)
CD4þ% at cART initiationb Median (Q1, Q3) 25 (17, 32)
Missing 315 (34%)
Time from cART initiation to failure (months) Median (Q1, Q3) 23 (14, 38)
cART, combination antiretroviral therapy; EI, entry inhibitor (including fusion inhibitor); INSTI, integrase strand transfer inhibitor; NNRTI,
nonnucleoside reverse transcriptase inhibitor; NRTI, nucleoside/tide reverse transcriptase inhibitor; PI, protease inhibitor.
aVirologic failure defined as a consecutive series (at least one month apart) of HIV viral load >1000copies/ml, at least 6 months after initiation of
cART regimen. Date of cART failure defined as date of confirmed viral load >1000copies/ml.
bNearest measure up to 6 months prior to or at cART initiation.
cIncluded ritonavir boosting where appropriate.(baseline), their median age was 11 years, their median
CD4þ% was 28% and their median log10 viral load was
3.8. Thirty-six percent had a previous AIDS-defining
condition. Eighty percent reported 100% adherence at
the time of virologic failure.
Figure 1 presents the proportion of children following
each treatment strategy after cART failure by time since
virologic failure. At 6 and 12 months after virologic
failure, 84 and 71%, respectively, of children had not
switched from their failing regimen. New cART
regimens were initiated in 8% at 6 months and in 16%
at 12 months. Few children switched to a drug-sparing
regimen (5%) or discontinued all antiretroviral drugs (7%)
by 12 months after virologic failure.
Thirty-one children with virologic failure switched to a
drug-sparing regimen within 6 months of follow-up
(Supplementary Table 1S, http://links.lww.com/QAD/
A752). Antiretroviral drugs included in drug-sparingregimens were variable, but the majority (68%) included
NRTIs only [single (23.8%), double (28.6%) or triple
(47.6%)]; 19% included a protease inhibitor and single
NRTI; 3% a single protease inhibitor; 3% a single
NNRTI and 6% a protease inhibitor and NNRTI
combination. Only one child received emtricitabine
monotherapy and none lamivudine.
Mean change from baseline CD4R% at
12 months after virologic failure
Children who switched to new cART and to a drug-
sparing regimen both had a nonsignificant mean increase
in CD4þ% from baseline (0.6 and 1.4 percentage points,
respectively) (Table 3). Children continuing a failing
cART regimen had a significant mean decrease in
CD4þ% by month 12. These changes in CD4þ% did not
differ significantly from those of children who switched
to new cART. Faring the worst were children who
discontinued all antiretroviral drugs, with a significant
mean decrease in CD4þ% of 3.2 percentage points from
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Table 2. Characteristics of the study population at the time of
virologic failure (NU735a).
Characteristic Total (N¼735a)
Sex
M 370 (50%)
F 365 (50%)
Race/ethnicity
White non-Hispanic/Other 87 (12%)
Black non-Hispanic 463 (63%)
Hispanic 180 (24%)
Missing 5 (1%)
Age (years)
Median (Q1, Q3) 11 (8, 14)
Previous CDC [21,22] class C
Yes 267 (36%)
No 468 (64%)
Height Z-score
Median (Q1, Q3) 0.53 (1.25, 0.20)
Weight Z-score
Median (Q1, Q3) 0.06 (0.81, 0.83)
Nadir CD4þ%
Median (Q1, Q3) 18 (11, 25)
CD4þ%
Median (Q1, Q3) 28 (20, 34)
Log10 viral load
Median (Q1, Q3) 3.79 (3.38, 4.26)
ARV adherence
<100% 150 (20%)
100% (80%)
ARV, antiretroviral; CDC, Centers for Disease Control and Prevention.
aThis table includes children who were used in the final analysis, as
they had all baseline covariate information available.
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Fig. 1. Treatment strategies following virologic failure, by
time since failure for those remaining in follow-up. The
horizontal axis represents time in months from VF through
follow-up to 12 months. The vertical axis presents the per-
centage of participants managed with the four treatment
strategies at each time point. The four strategies include
continue with current failing cART; switch to a new cART;
switch to a non-cART, drug-sparing regimen and discontinue
all ART. These different treatment strategies are indicated by
different shades on the bar graph at each time point. Numbers
of participants (N) are those retained in the cohort at each time
period: baseline, 3, 6, 9 and 12 months.baseline levels, which differed significantly from that of
those who switched to a new cART regimen.
Mean change from baseline viral load at
12 months after virologic failure
All four treatment strategies yielded mean decreases in
log10VL from baseline to 12 months after virologic
failure, and these decreases were significant for all but the
antiretroviral drug discontinuation group (Table 3).
Children who switched to new cART saw the largest
reduction in log10 viral load, followed by those who
switched to a drug-sparing regimen, and finally, those
who stayed on their failing cART. The decrease in viral
load for children who switched to new cART did not
differ significantly from that of the drug-sparing group
but was significantly larger than for those who made noTable 3. Mean change from baseline CD4R% and log10 viral load at 12
Characteristics Continue failing cART New
Person-time (years) 612 324
CD4þ% changes
Parameter estimate 0.64 0.59
95% confidence interval 1.10 to 0.17 1.01 t
P 0.15 R
log10 viral load change
Parameter estimate 0.27 1.15
95% confidence interval 0.34 to 0.20 1.41 t
P <0.001 R
ARVs, antiretrovirals; cART, combination antiretroviral therapy.change from their failing cART and those who
discontinued antiretroviral drugs entirely.
All above estimates were derived from weighted outcome
models. The estimates did not materially change whenwe
used unweighted models with or without baseline
covariates (data not shown).Discussion
Our study provides evidence that in children with
virologic failure, stopping all ART results in the worstmonths after combination antiretroviral therapy failure (NU735).
cART Drug-sparing regimen Discontinue ARVs
293 306
1.40 3.18
o 2.19 1.56 to 4.37 5.25 to 1.11
ef 0.64 0.004
0.85 0.20
o 0.88 1.35 to 0.34 0.65 to 0.26
ef 0.30 <0.001
2114 AIDS 2015, Vol 29 No 16immunologic and virologic outcomes at 12 months and
should be avoided. We found that children who stopped
ART had a significantly greater decline in CD4þ%
[3.18 percentage points (95% CI 5.25 to 1.11)] at
12 months after virologic failure than those who switched
to new cART (P¼ 0.04). Siberry et al. [18] reported from
the overlapping AMP cohort that children who had an
unplanned treatment interruption saw a steady decline in
CD4þ% and count with median (range) slopes of0.66%
(3.54 to þ1.34%) and 12.7 cells/ml (148 to
þ31 cells/ml) per month, with no comparison group
included in this report. Gibb et al. [23] found a similar rate
of CD4þ% decline with unplanned treatment interrup-
tions in a cohort from the United Kingdom, Ireland and
Rotterdam. The Paediatric European Network for
Treatment of AIDS (PENTA) 11 Trial Team study
reported that even in children with good immunological
recovery and virologic suppression, planned treatment
interruptions resulted in rapid CD4þ cell count decline,
particularly in the first 12 weeks, stabilizing through 48
weeks [24]. These findings, together with our study,
suggest that where possible, treatment interruptions
should be avoided in HIV-infected children with
virologic failure.
We found that the majority of children (73%) with
virologic failure remained on failing cART through
12 months, a decision made by the patient, the family and
their clinicians. Continuing a failing cART regimen
resulted in a significant decrease in CD4þ% from baseline,
but this change was not significantly different from the
group starting new cART. Children who switched to new
cART, however, had significantly higher viral load
suppression at 12 months than those remaining on a
failing cART regimen. Delayed switching of cART in
children, adolescents and adults is not uncommon in large
observational cohorts. The Collaborative HIV Paediatric
Study (CHIPS) cohort report from 2005 that of 22%
children who switched to second-line therapy for
virologic failure, children who never achieved virologic
suppression (<400 copies/ml) switched at a median of 3.2
years after cART initiation [25]. From resource-limited
settings, Davies et al. [11], from the Southern African
IeDEA cohort including seven South African Paediatric
HIV Treatment sites between 1999–2008, report that of
254 children identified with virologic failure on first-line
ART and at least 1 year of follow-up, only 38% switched
to second line. Given that ART rollout in South Africa
began in April 2004 with limited access to ART for some
children between 2001 and 2003, we can assume that
most of these children remained on failing ART in an era
when second-line drugs were available in South Africa
[11]. Similarly, in a South African adult cohort between
2003 and 2008 with confirmed virologic failure on first-
line ART, after 6 months of follow-up, only 21.6% were
switched to second-line therapy [26]. The reasons for this
are multiple and include availability of second and third-
line regimens, treating clinician experience and mostimportantly concerns about switching a child or
adolescent to a new regimen when adherence remains
suboptimal. The PENTA and the Pediatric AIDS Clinical
Trials Group (PACTG/IMPAACT) (PENPACT-1) study
randomized children with virologic failure receiving
either protease inhibitor based or NNRTI-based cART
to switch to a new cART at either a low (viral load
>1000 copies/ml) or a high threshold (viral load
>30 000 copies/ml) [16]. This study found that immuno-
logical outcomes in children receiving a protease
inhibitor based regimen did not differ between low
and high-threshold groups at the time of switch. Adult
studies have also shown that immunological well being is
maintained on a failing protease inhibitor based regimen
[27]. More specifically, Peterson et al. [28] found that a
delayed switch from a failing protease inhibitor-based
regimen in adults was not associated with an increase in
mortality and immunological deterioration, but with
NNRTI-based therapy, a switch beyond 3 months from
virologic failure was associated with such increases. Our
study was not able to directly compare outcomes after
delayed switch from protease inhibitor or NNRTI-based
regimens. Concern about ongoing accumulation of viral
resistance mutations during continuation of a failing
cART regimen may influence decisions regarding this
strategy in children with virologic failure. In the
PENPACT-1 study, although the M184V mutation was
most common in both groups, there was no accumulation
of NRTI resistance mutations in the protease inhibitor
based high-threshold group [16]. In children receiving an
NNRTI-based regimen, there was an accumulation of
resistance mutations, particularly NRTI mutations, in the
high-threshold group conferring high-level resistance to
zidovudine, didanosine, stavudine and abacavir [16].
Therefore, on the basis of these studies, children failing
NNRTI-based regimens should be switched early,
although there may be less urgency in those failing
boosted protease inhibitor based regimens.
Data to support the evaluation of drug-sparing strategies
in this study are limited, as only 5% of our study
population were receiving a drug-sparing regimen at
12 months of follow-up after virologic failure. Evaluation
was difficult due to the small number of children
receiving this strategy and the heterogeneity of selected
holding regimens, although 68% of children received one
or more NRTIs, only one child received emtricitabine
monotherapy and a number of children in the drug-
sparing regimen group received potentially suppressive
ARTwith two drug classes included. When developing
this study, our criterion defining cARTwas strict and it is
possible that children classified in the ‘drug-sparing
regimen’ group received potentially robust regimens that
may have improved their outcomes. Few studies have
evaluated drug-sparing regimens in children. Most
recently, the IMPAACT P1094 study, a randomized
controlled study evaluated continuing a failing ART
regimen compared with lamivudine/emtricitabine
Virological failure in HIV-infected youth Fairlie et al. 2115(3TC/FTC)monotherapy in poorly adherent 8 to 24 year
olds. The study was halted early due to slow recruitment
and only 33 children were enrolled (16 continued a failing
regimen, 17 switched to 3TC/FTC monotherapy). After
28 weeks on study, those switched to 3TC/FTC were
more likely to sustain a 30% decline in absolute CD4þ
[29]. Abadi et al. [17] demonstrated that children who
stopped their protease inhibitor-based therapy and
continued with an NRTI-based regimen, that is partial
treatment interruption, did not progress clinically and
remained relatively stable immunologically. The
ARROW study reported that after induction with
protease inhibitor or NNRTI-based regimens, children
switched to triple NRTIs maintained virological suppres-
sion in the short term (24 weeks) but by 144 weeks,
virological suppression rates were significantly lower [30].
A small South African study (23 children) showed a 23%
reduction in CD4þ cell count at 6 months of follow-up in
children who switched to lamivudine monotherapy; 30%
restarted a cARTregimen [31]. Adult studies have shown
that immunologic stability can be maintained with
lamivudine monotherapy, albeit with larger declines in
CD4þ cell count among those previously treated with
protease inhibitor based regimens [32]. Drug-sparing
regimens might, therefore, serve as a useful stopgap
treatment approach when there are significant barriers
to starting new cART (such as persistent adherence
problems and/or lack of availability of active drugs or
toxicity), as theymay be easier to administer, have less side
effects than cART, have lower risk of resistance mutation
accumulation and stability might persist in the presence of
incomplete adherence. However, considering the lack of
available data, children continuing this strategy require
careful follow-up [8,33,34].
Resolving adherence issues remains the most important,
yet most difficult factor in managing children with
virologic failure. Adherence problems may be related to
patient/caregiver and/or healthcare provider factors
[35,36]. We found that most children who experienced
virologic failure initiated cART prior to 2006 and that
nelfinavir was the most commonly prescribed failing
cART drug, followed by lopinavir/ritonavir. It is likely
that poor palatability of these drugs, side effects such as
nausea and vomiting and a large pill burden contributed
to poor adherence and subsequent virologic failure in this
cohort. Ongoing efforts to increase the palatability of
paediatric drugs and to simplify regimens with fixed-dose
combination drugs are hoped to increase adherence.
Adherence interventions in children and adolescents need
to be tailored to the personal circumstances of the index
case and their family and caregivers and require a
multidisciplinary, dynamic approach. Interventions may
include, but are not limited to simplification of ART
regimens as far as possible; treating associated side effects;
reminders to trigger adherence such as alarms; psycho-
social interventions that may be individual or group-
based; mental health screening and management;appropriate disclosure of HIV status to the child;
minimizing transport costs for clinic attendance and
directly observed therapy in children and adolescents
taking cART in extreme cases [36]. Although this study
was based in a resource-rich setting, as increasing
numbers of children in low and middle-income countries
start cART early, a proportion will experience virologic
failure and clinicians will require access to second and
third-line cART, currently scarce in these settings,
creating treatment dilemmas for this increasing popu-
lation.
Limitations
This study has limitations. The validity of our estimates of
change in immunologic and virologic outcomes by
treatment strategy after virologic failure is based on the
assumption that we appropriately accounted for all
confounders. Although we collected information on
prognostic characteristics we believe would strongly
predict choosing one treatment strategy over the altern-
atives, we did not have information on resistance, a key
variable that may be associated with choosing a particular
treatment strategy and immunologic and virologic
outcomes. Adherence data were also not uniformly
collected in this study population, although we were able
to utilize all available data. Lastly, the period of follow-up
after virologic failure was relatively brief. However, this
study provides detailed analysis on a robust number of
participants and our results remained stable across the
crude, baseline-adjusted and weighted models as well as
with several sensivity analyses.
Conclusion
Managing virologic failure in children remains challen-
ging. Compared with switching to new cART, which
requires optimized adherence and available cART,
continuing a failing cART regimen results in similar
12-month immunologic outcomes while discontinuing
ART is the worst option immunologically and virolo-
gically and should be avoided in children with virologic
failure. Switching to a drug-sparing regimen may be a
well tolerated option in the short-term, but data
regarding the sustainability of this strategy remain scarce
and careful follow-up is required.Acknowledgements
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